Skip to main content
. 2017 Jul 6;7:4792. doi: 10.1038/s41598-017-05029-1

Figure 6.

Figure 6

Dasatinib inhibits cell proliferation in MRMT1-luc2 cells in a dose-dependent manner in vitro. MRMT1-luc2 cells were treated with increasing concentrations of dasitanib for 48 h and assayed by the (a) MTT assay, (b) the BrdU assay, and (c) the RealTime-Glo™ assay. IC50, the concentration needed to inhibit viability or proliferation by 50. Data were normalized to cells treated with 0.1% DMSO (negative controls, 100% activity) and blank controls, e.g. wells without cells (0% activity) and expressed as percentage of these controls. Data are displayed as mean ± SEM. Normalized response is compared to common log of dasatinib concentration (µM) and the IC50 calculated using a variable slope. Data from the MTT assay represents one of three independent experiments done in quadruplicates. Data from the BrDU and RealTime-Glo™ assays represents one experiment done in triplicates to confirm the results from the MTT assay.